Shares of Viridian Therapeutics (VRDN) are moving lower after Amgen’s (AMGN) Phase 3 trial of Tepezza administered by subcutaneous injection via an on-body injector in participants with moderate-to-severe active thyroid eye disease met the primary and secondary endpoints. Viridian is also developing a treatment for thyroid eye disease. The stock in morning trading is down 19%, or $3.61, to $15.23.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Evercore cuts Viridian price target, removes from ‘Tactical Outperform’ list
- Viridian Therapeutics price target lowered to $37 from $44 at Wedbush
- Viridian Therapeutics price target lowered to $20 from $29 at Wells Fargo
- Viridian Therapeutics price target lowered to $36 from $41 at Goldman Sachs
- Viridian Therapeutics price target lowered to $22 from $34 at H.C. Wainwright